{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-024290","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.765284+00:00","generated_at":"2026-06-14T14:52:18.002086+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay reports complete dose escalation data for RLY-4008; 73% ORR in FGFRi-naïve CCA at pivotal dose","bullets":["Among FGFRi-naïve FGFR2-fusion CCA patients at or above 70mg QD (n=11): 73% ORR, median DoR 11.2 months.","Patients at lower doses (n=14): 36% ORR; median DoR 5.6 months.","Safety consistent with prior data: no Grade 4/5 AEs; off-target hyperphosphatemia/diarrhea clinically insignificant.","Data cut-off Jan 30, 2023; presentation at ASCO on June 4, 2023.","Pivotal cohort enrollment completion and initial non-CCA expansion data expected in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-024290","json":"https://secwatch.observer/filing/0000950170-23-024290.json","markdown":"https://secwatch.observer/filing/0000950170-23-024290.md","text":"https://secwatch.observer/filing/0000950170-23-024290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023024290/0000950170-23-024290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023024290/rlay-20230525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:52:18.002086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}